Scarica l'app Stockscreener
0.6881
0.71%
-0.0049
Xilio Therapeutics Inc Borsa (XLO) Ultime notizie
Xilio Therapeutics Executives Increase Holdings - TradingView
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World
Xilio Therapeutics Expands Authorized Shares at Annual Meeting - TipRanks
Xilio Therapeutics Appoints Akintunde Bello to Board of Directors - citybiz
Xilio Therapeutics appoints oncology veteran Akintunde Bello to board By Investing.com - Investing.com South Africa
Xilio Therapeutics expands board, elects new director - Investing.com Australia
Xilio Therapeutics expands board, elects new director By Investing.com - Investing.com South Africa
Xilio Therapeutics Expands Board with New Director - TipRanks
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - The Manila Times
Xilio Therapeutics appoints oncology veteran Akintunde Bello to board - Investing.com
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., To Its Board Of Directors - MarketScreener
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of Directors - Nasdaq
Bristol Myers Squibb Oncology Leader Joins Xilio Board: Key Boost for Novel Cancer Immunotherapy Programs - Stock Titan
Leadership Experience 2025: Starbucks Rallies 14,000 North America Coffeehouse Leaders to Accelerate its 'Back to Starbucks' Strategy - The Globe and Mail
Uranium Royalty Corp. Announces U.S.$30 Million Bought Deal Financing - The Globe and Mail
Musk-Trump Messy Breakup Wipes Out $150B in TSLA Stock: What's Next? - The Globe and Mail
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering - GlobeNewswire
Xilio Therapeutics Announces $50 Million Public Offering and Potential $150 Million in Total Gross Proceeds - Nasdaq
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering - GlobeNewswire Inc.
Market Analysis: June 4th, 2025 - The Globe and Mail
International Resources Holding Enters into Agreement to Acquire Majority Interest in Alphamin Resources Corp. from Tremont Master Holdings - The Globe and Mail
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Biotech Startup Xilio Awards $194K Worth of Stock Options Under Nasdaq Compliance Plan - Stock Titan
Xilio Therapeutics Inc (NASDAQ: XLO) Is Down -26.69% Year-To-Date, But Analysts Find Room For A Price Rally - Stocksregister
Form 424B5 Xilio Therapeutics, Inc. - StreetInsider
Xilio Therapeutics announces public offering of warrants By Investing.com - Investing.com South Africa
Xilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug Trial - MSN
Xilio Therapeutics tumbles after $50 mln equity offering - TradingView
Xilio Therapeutics (XLO) Launches Public Offering of Warrants | - GuruFocus
Xilio Therapeutics announces pricing of $50 million public offering - MSN
Xilio Therapeutics (XLO) Launches Public Offering of Warrants | XLO Stock News - GuruFocus
Xilio Therapeutics (XLO) Stock Dips Following Public Offering Announcement - GuruFocus
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering - The Manila Times
Xilio Therapeutics Secures $150M Potential Funding Through Strategic Warrant Offering for Cancer Therapies - Stock Titan
Xilio Therapeutics Announces Proposed Public Offering - marketscreener.com
Xilio Therapeutics (XLO) Launches Public Offering for Warrants | - GuruFocus
SEC Form 424B5 filed by Xilio Therapeutics Inc. - Quantisnow
Xilio Therapeutics drops on equity raise plans - TradingView
Xilio Therapeutics Presents Phase 2 Trial Data Update - TipRanks
Xilio Therapeutics announces public offering of warrants - Investing.com
Xilio Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Pre-Funded Warrants and Series A, B, and C Warrants - Nasdaq
Immuno-Oncology Biotech Xilio Therapeutics Unveils Complex Public Offering With Multiple Warrant Series - Stock Titan
Xilio Therapeutics (XLO) Reveals Positive Phase 2 Trial Data for Cancer Treatment | XLO Stock News - GuruFocus
Xilio Therapeutics Announces Updated Phase 2 Data for - GlobeNewswire
Xilio Therapeutics Reports Preliminary 26% Objective Response Rate in Phase 2 Trial of Vilastobart Combined with Atezolizumab for Metastatic MSS Colorectal Cancer - Nasdaq
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - The Manila Times
Xilio Therapeutics Announces Updated Phase 2 Data For Vilastobart, A Tumor-Activated Anti-Ctla-4, In Combination With Atezolizumab In Patients With Metastatic Microsatellite Stable Colorectal Cancer - marketscreener.com
Breakthrough: New Immunotherapy Achieves 26% Response Rate in Hard-to-Treat Colorectal Cancer Patients - Stock Titan
Xilio Therapeutics Reports Q1 2025 Financial Results - TipRanks
Thinking Of Buying Xilio Therapeutics Inc (NASDAQ: XLO) Stock? Here Is What You Should Know - Stocksregister
Xilio Therapeutics (NASDAQ:XLO) Upgraded at Wall Street Zen - Defense World
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):